Charles River Laboratories International, Inc. (NYSE:CRL) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $103.31 and last traded at $103.45, with a volume of 184,665 shares. The stock had previously closed at $101.21.

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research note on Thursday, August 10th. Barclays PLC set a $90.00 target price on shares of Charles River Laboratories International and gave the stock a “hold” rating in a research note on Saturday, May 13th. Jefferies Group LLC reaffirmed a “buy” rating and set a $121.00 target price on shares of Charles River Laboratories International in a research note on Friday, June 30th. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $95.00 target price (up previously from $89.00) on shares of Charles River Laboratories International in a research note on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $96.94.

The company has a market cap of $4.93 billion, a price-to-earnings ratio of 27.31 and a beta of 1.02. The company has a 50-day moving average of $99.78 and a 200-day moving average of $92.92.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. Charles River Laboratories International’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.20 earnings per share. Equities research analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase program on Wednesday, May 10th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

In other news, insider William D. Barbo sold 4,000 shares of Charles River Laboratories International stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the transaction, the insider now owns 20,424 shares in the company, valued at $2,040,561.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Davide Molho sold 10,976 shares of Charles River Laboratories International stock in a transaction on Friday, May 26th. The shares were sold at an average price of $92.84, for a total value of $1,019,011.84. Following the transaction, the insider now owns 27,525 shares in the company, valued at approximately $2,555,421. The disclosure for this sale can be found here. Insiders have sold 85,921 shares of company stock worth $8,417,291 over the last ninety days. 2.20% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares in the last quarter. Riverhead Capital Management LLC increased its position in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after buying an additional 247 shares in the last quarter. Cambridge Advisors Inc. acquired a new position in shares of Charles River Laboratories International during the second quarter worth $202,000. Advisor Partners LLC acquired a new position in shares of Charles River Laboratories International during the second quarter worth $208,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Charles River Laboratories International during the second quarter worth $217,000. Institutional investors and hedge funds own 93.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/23/charles-river-laboratories-international-inc-crl-hits-new-52-week-high-at-103-31-2.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.